Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Epigenomics AG

Market Cap 767K 880K 711K 665K 1.25M 83.04M 1.26M 8.43M 3.27M 40.88M 3.3M 3.23M 142M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.73M 13.46M 10.87M 10.17M 19.08M 1.27B 19.2M 129M 49.97M 625M 50.52M 49.44M 2.17B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 01/02/2024
Director TitleAgeSince
Chairman 58 01/03/2023
Director/Board Member 55 01/06/2020
Director/Board Member 56 05/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
+4.56%+13.31%+99.96%+105.56% 4.28B
+4.47%-0.40%+67.43%+108.94% 2.81B
+3.92%+3.83%-25.97%-38.60% 2.01B
-0.51%-4.17%+91.67%-51.85% 1.75B
+11.50%+13.97%+37.57%+228.89% 1.35B
-3.47%-0.89%-17.75%+17.55% 837M
-0.38%+4.42%+158.71%-62.26% 767M
-10.32%-23.08%+54.07% - 596M
-1.73%-5.87%-30.10%-17.39% 508M
Average +0.89%-0.83%+48.40%+36.35% 1.66B
Weighted average by Cap. +2.98%+2.78%+60.33%+59.87%

Financials

2024 2025
Net sales - 24K 27.53K 22.23K 20.81K 39.02K 2.6M 39.26K 264K 102K 1.28M 103K 101K 4.44M
Net income -3.35M -3.84M -3.1M -2.91M -5.45M -363M -5.48M -36.83M -14.27M -179M -14.43M -14.12M -620M -314K -360K -291K -272K -511K -33.98M -514K -3.45M -1.34M -16.73M -1.35M -1.32M -58.08M
Net Debt 10.46M 11.99M 9.68M 9.06M 17M 1.13B 17.1M 115M 44.52M 557M 45.01M 44.05M 1.93B 10.97M 12.58M 10.16M 9.51M 17.83M 1.19B 17.94M 120M 46.7M 584M 47.22M 46.2M 2.03B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!